Bristol-Myers Squibb (NYSE:BMY) has been assigned a $62.00 target price by equities researchers at Credit Suisse Group in a research report issued to clients and investors on Monday. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective suggests a potential downside of 2.25% from the company’s previous close.
BMY has been the subject of a number of other reports. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 26th. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price target for the company. in a research note on Friday, December 22nd. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, Jefferies Group cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price target for the company. in a research note on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $65.38.
Bristol-Myers Squibb (BMY) traded up $0.15 during mid-day trading on Monday, hitting $63.43. 5,896,004 shares of the company were exchanged, compared to its average volume of 6,090,000. Bristol-Myers Squibb has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The stock has a market cap of $103,820.00, a PE ratio of 24.97, a PEG ratio of 2.16 and a beta of 1.18.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the sale, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. WoodTrust Financial Corp purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $498,000. Comprehensive Portfolio Management LLC lifted its position in shares of Bristol-Myers Squibb by 280.6% in the 4th quarter. Comprehensive Portfolio Management LLC now owns 18,325 shares of the biopharmaceutical company’s stock worth $1,123,000 after purchasing an additional 13,510 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management lifted its position in shares of Bristol-Myers Squibb by 79.5% in the 4th quarter. Livingston Group Asset Management CO operating as Southport Capital Management now owns 12,449 shares of the biopharmaceutical company’s stock worth $763,000 after purchasing an additional 5,512 shares during the period. Bredin Investment LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $1,937,000. Finally, Howard Capital Management lifted its position in shares of Bristol-Myers Squibb by 0.5% in the 4th quarter. Howard Capital Management now owns 176,010 shares of the biopharmaceutical company’s stock worth $10,786,000 after purchasing an additional 804 shares during the period. 69.75% of the stock is owned by hedge funds and other institutional investors.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
